Axsome Therapeutics, Inc.

NasdaqGM:AXSM Rapporto sulle azioni

Cap. di mercato: US$4.2b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Axsome Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Axsome Therapeutics ha un patrimonio netto totale di $102.9M e un debito totale di $179.3M, che porta il suo rapporto debito/patrimonio netto a 174.4%. Le sue attività totali e le sue passività totali sono rispettivamente $548.2M e $445.4M.

Informazioni chiave

174.4%

Rapporto debito/patrimonio netto

US$179.33m

Debito

Indice di copertura degli interessin/a
ContantiUS$315.66m
Patrimonio nettoUS$102.85m
Totale passivitàUS$445.37m
Totale attivitàUS$548.23m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Aug 06

Axsome Therapeutics: Lots Of Moving Parts

Jul 23

Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Jul 02
Health Check: How Prudently Does Axsome Therapeutics (NASDAQ:AXSM) Use Debt?

Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments

May 10

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Apr 13
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Mar 17
Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?

Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges

Feb 21

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Dec 27
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Dec 12
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Sep 12
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Aug 08
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues

Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

May 13
Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts

Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 03
Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Mar 01
Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?

Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Nov 14
Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?

Axsome Therapeutics: Clear Path Ahead For AXS07

Oct 05

Axsome to resubmit marketing application for migraine therapy in Q3 2023

Sep 29

Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity

Sep 16

Axsome begins enrolling in late-stage study of migraine drug AXS-07

Sep 01

Axsome gains 19% as FDA approves depression therapy

Aug 19

Axsome Therapeutics Q2 2022 Earnings Preview

Aug 08

Axsome: Breaking Bearish Trend

Jul 26

Axsome: One Step At A Time

Jul 01

Axsome And AXS-05: A Special Situation

May 02

Axsome: A Growth Transition

Apr 13

Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst

Apr 03

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $463.0M ) di AXSM superano le sue passività a breve termine ( $186.6M ).

Passività a lungo termine: Le attività a breve termine di AXSM ( $463.0M ) superano le sue passività a lungo termine ( $258.8M ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: AXSM ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di AXSM è aumentato da 80.6% a 174.4% negli ultimi 5 anni.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: AXSM ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Dati insufficienti per determinare se AXSM ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.


Scoprire le aziende sane